Isoniazid Induced Liver Injury; a Case Series and Review

Anusha, R Jerlin; Chand, Sharad; Lal, Varun; Sushmitha, Devarapu Mary; Reddy, Dhypa Sahithi; Tejaswini, S M; Chitrahasini, Savanthi

doi:10.5530/jppcm.2018.2.30

Cited by 7 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although CYP2E1 c1/c1 was present in both the DILI and non-DILI groups, the genotypes C/D or C/C were three times more likely to result in anti-TB DILI. The same study showed that the risk of DILI went up when the NAT2 gene polymorphism was combined with the CYP2E1 C/D or C/C genotype [33,38,39].…”

Section: Mechanism Of Liver Injurymentioning

confidence: 88%

“…The hepatic NAT2 gene is polymorphic in humans, and rapid acetylation is associated with one or more wild-type NAT2*4 alleles, while slow acetylation is related to two or more variant alleles of the NAT2 gene [31]. Acetylation activity in vitro decreases when the NAT2*4 > NAT2*7 > NAT2*6 > NAT2*5 alleles are inherited [32][33][34]. In their initial study, which involved genotyping acetylator status in 224 participants receiving anti-TB treatment, Huang, et al found that individuals with NAT2 genotypes associated with delayed acetylation had a four-fold risk of developing INH-induced hepatotoxicity [35] and Likewise, a recent meta-analysis of 14 trials with 474 cases and 1446 controls led to the same conclusions, with a 4.6 odds ratio favoring slow acetylators [36].…”

Section: Mechanism Of Liver Injurymentioning

confidence: 99%

See 1 more Smart Citation

Isoniazid-induced hepatic injury: a case report and its mechanism of liver injury

Selvaraj¹,

Dhamothrasamy²,

Duraisamy³

et al. 2022

J Adv Pharm Educ Res

View full text Add to dashboard Cite

show abstract

Section: Mechanism Of Liver Injurymentioning

confidence: 88%

Section: Mechanism Of Liver Injurymentioning

confidence: 99%

Isoniazid-induced hepatic injury: a case report and its mechanism of liver injury

Selvaraj¹,

Dhamothrasamy²,

Duraisamy³

et al. 2022

J Adv Pharm Educ Res

View full text Add to dashboard Cite

show abstract

“…Chemotherapy-induced peripheral neuropathy (CIPN) is a main complication related to cancer treatment (Miltenburg and Boogerd, 2014). Adverse drug reactions are unwanted and noxious effects due to therapy which complicates the dis-ease burden (Rachana et al, 2019;Anusha et al, 2018). Adverse drug reactions may range from mild to severe and may increase the length of hospital stay (Chand et al, 2019;Voora et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Cisplatin-Induced Peripheral Neuropathy: An Observational Descriptive Study

Kurian¹,

Babu²,

Punnoose³

et al. 2020

ijrps

View full text Add to dashboard Cite

Peripheral neurotoxicity is a major adverse effect of cisplatin chemotherapy. A prospective observational study was conducted among 200 cancer patients who received cisplatin between October 2017 and March 2018 to evaluate the occurrence, causality and severity of cisplatin induced peripheral neuropathy. A suitable data collection form was used to record patient information required for the study. Peripheral neuropathy was assessed using the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE). As per the results, 19 (9.5%) patients developed peripheral neuropathy after receiving cisplatin therapy. Peripheral neuropathy was reported higher in males (84.2%) compared to females (15.7%) and more within the age group of 58-65 years (38.6%). Most of the patients developed Grade I neuropathy (84.2%), followed by Grade II neuropathy (15.7%). The study concluded that the severity of peripheral neuropathy increases with higher cumulative doses of cisplatin.

show abstract

“…This condition is managed by using different treatment modalities such as radiotherapy, surgery and chemotherapy. Adverse drug reaction is regarded as a signi icant consequence of chemotherapeutic drugs; therefore, they cannot be prescribed in larger doses to treat cancer (Mrugank and Hareesha, 2013) and (Anusha et al, 2018). There is always a risk of adverse drug reactions associated with the intake of medicines (Rachana et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Adverse Drug Reactions and its Management Associated with Cancer Chemotherapy

Sanija¹,

P²,

K³

et al. 2020

ijrps

View full text Add to dashboard Cite

Adverse Drug Reactions () are the problem that adds extra burden in the global scenario. Anticancer drugs can lead to severe negative consequences due to these . This study was conducted to assess the causality, severity and preventability of the identified of chemotherapeutic drugs among hospitalized patients diagnosed with cancer and also to analyze its management. A prospective observational study was conducted among cancer patients for a period of eight months. A total of 120 hospitalized patients who developed at least one ADR due to chemotherapy were included in this study. Data were collected and documented in a well-designed data collection form. A total of 166 were detected in 120 patients. 33(19.8%), was found as the most commonly identified ADR. Patients administered with as were found to be reported with the highest number of (36). According to Naranjo’s scale and WHO causality assessment, 110(66.2%) and 105(63.2%) were found probable. & scale of severity showed that 97(58.4%) were moderate and Modified and Thornton scale revealed that 129(77.7%) were not preventable. The patients prescribed with , , regimen should be strictly and continuously monitored for the symptoms of ADR. Early detection of ADR can decrease morbidity and mortality.

show abstract

Isoniazid Induced Liver Injury; a Case Series and Review

Cited by 7 publications

References 6 publications

Isoniazid-induced hepatic injury: a case report and its mechanism of liver injury

Isoniazid-induced hepatic injury: a case report and its mechanism of liver injury

Cisplatin-Induced Peripheral Neuropathy: An Observational Descriptive Study

Adverse Drug Reactions and its Management Associated with Cancer Chemotherapy

Contact Info

Product

Resources

About